Simplify Logo
Jazz Pharmaceuticals

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Associate Director - Leadership Development and Skills Enablement

Full-Time
$156k - $234k/yr
Expert
Bachelor's, Master's, MBA
Pennsylvania, USA
Remote

Travel of 50–60% is required.

About the job

Requirements
  • A Bachelor's degree in business, healthcare, organizational psychology, or a related field is required.
  • Ten years of industry experience in Learning & Development, Leadership Development, Human Resources, or relevant field-based leadership roles is required.
  • At least two years of experience in training, with a proven track record of developing and delivering engaging training solutions using adult learning principles and distance learning methodologies.
  • Leadership experience developing skills models and collaborating cross-functionally to drive capability building across field and corporate teams.
  • Experience working in a product operating model.
  • Strong understanding of leadership development frameworks, skills and competency modeling, and the operational dynamics of sales, medical, and market access field teams.
  • Strong understanding of the product operating model, including its design, key roles, and ways of working.
  • Working knowledge of commercial and medical data concepts to help leaders make data-informed decisions.
  • Expertise in adult learning principles, instructional design, content development, and training delivery.
  • Proficiency with learning management systems, virtual training tools, and Microsoft Office Suite.
  • Experience designing and delivering role-based training using adult learning principles.
  • Ability to operate effectively in a matrixed enterprise environment.
  • Experience developing training metrics and measuring learning impact and outcomes.
  • Ability to facilitate sessions for individual contributors and senior leaders.
  • Ability to craft purposeful narratives that explain change, inspire action, and align people around a shared direction.
  • Ability to move work forward, shape decisions, and drive outcomes through collaboration and trust rather than formal authority.
  • Ability to navigate shifting demands, manage competing priorities, and maintain progress.
  • Ability to adopt new tools, ways of working, and behaviors with confidence and practical improvement.
  • Ability to improve processes and products through reflection and iteration and generate new approaches when constraints exist.
  • Ability to engage, motivate, and influence stakeholders at all levels to build alignment, commitment, and momentum.
  • Ability to travel 50–60% of the time.
Responsibilities
  • Own and execute the enterprise learning strategy for Leadership Development, establishing global curricula, skill development pathways, and role-based learning experiences for emerging, first-line, and senior leaders aligned with enterprise priorities and transformation initiatives.
  • Lead the creation, evolution, and implementation of cohesive, customer-centric skills models for sales, medical, and market access field roles to align with organizational goals and high-performance behaviors.
  • Serve as a strategic advisor to Medical, Market Access, Sales, Operations, and Marketing leadership on leadership-development priorities, skills gaps, and organizational readiness.
  • Design and scale role-based capability-development programs that strengthen coaching, strategic decision-making, performance management, and leading through change by translating frameworks into practical learning experiences.
  • Advance skills evolution, customer-centric ways of working, and performance improvement through integrated learning, change-management, and capability-building strategies.
  • Partner with cross-functional and Data & Enablement leaders to develop learning solutions that build understanding and adoption of the Global Capability Operating Model, including roles, responsibilities, decision rights, and enterprise ways of working.
  • Develop and oversee learning programs that enable leaders to understand, interpret, and appropriately apply enterprise data and insights to drive strategic decisions and coach their teams.
  • Present leadership-capability insights, adoption metrics, risks, recommendations, and organizational-readiness assessments to executive leadership teams.
  • Establish measurement frameworks to assess learning effectiveness, skills adoption, behavior change, and organizational impact, using stakeholder feedback and performance metrics to evolve learning priorities.
  • Build organizational capability within the Learning & Development function through mentoring, knowledge sharing, and best-practice development.
  • Collaborate with Medical, Market Access, Sales, Operations, Marketing, and Compliance to ensure leadership and skills content is accurate, practical, and compliant.
  • Collaborate with Global Capability Teams and Compliance partners to ensure accuracy, alignment, and appropriate-use guidance.
  • Collaborate with adjacent Learning & Development team members to maintain curriculum alignment.
  • Engage regional stakeholders to drive consistent adoption while accounting for local needs.
  • Share insights, risks, and lessons learned with Learning & Development and customer-experience peers and team leadership to support alignment and continuous improvement.
Desired Qualifications
  • Experience in pharmaceuticals or other highly regulated industries.
  • An advanced degree, such as an MBA, a Master of Science in Organizational Development, or another relevant graduate degree.
  • Experience working in a product operating model.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ziihera's August 2026 FDA win expands Jazz into a $3 billion-to-$5 billion opportunity.
  • Q2 2026 revenue reached $1.21 billion, and guidance rose to $4.60 billion-$4.75 billion.
  • Actio Biosciences acquisition closed September 15, 2026, adding KCNT1+ epilepsy upside.

What critics are saying

  • Tris Pharma filed generic Xywav and Xyrem applications in January 2026, threatening 2027 pricing.
  • Long-term debt was $4.4 billion at June 30, 2026, limiting flexibility for pipeline deals.
  • Zepzelca's failed second-line SCLC trial narrows growth if first-line maintenance adoption slows.

What makes Jazz Pharmaceuticals unique

  • Xywav's low-sodium profile keeps narcolepsy and idiopathic hypersomnia patients on therapy.
  • Ziihera became Jazz's first FDA-approved HER2-targeted backbone for first-line GEA on August 25, 2026.
  • Jazz combines rare sleep, epilepsy, and oncology commercialization across one scaled specialty platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.